黄斑浮腫と黄斑変性の世界市場レポート 2025年

黄斑浮腫と黄斑変性市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は7.1%で137億1,000万米ドルに成長します。予測期間の成長は、個別化医療へのアプローチ、新興市場における認知度の上昇、併用療法への注力、遠隔眼科サービスとの統合、世界の高齢化などに起因すると考えられます。予測期間の主な動向としては、徐放性ドラッグデリバリーの進歩、遺伝子治療の統合、新規画像技術の開発、バイオマーカーに基づく個別化治療アプローチ、遠隔モニタリングのための遠隔眼科、診断のための人工知能の進歩などが挙げられます。

糖尿病人口の増加が黄斑浮腫と黄斑変性市場の成長を牽引すると予想されます。糖尿病は、血液中のグルコース（糖）レベルの上昇を特徴とする慢性疾患で、目の血管を損傷し、黄斑浮腫と黄斑変性を引き起こす可能性があります。例えば、2024年6月、英国の公的医療制度であるナショナル・ヘルスケア・サービス（NHSイングランド）は、2023年にイングランドで糖尿病予備軍と診断された人の数が3,615,330人に上り、2022年の3,065,825人から18％増加したと報告しました。さらに、40歳未満の患者数は25％近く増加し、2022年の173,166人から2023年には216,440人に増加しました。このように、糖尿病人口の増加が黄斑浮腫と黄斑変性市場の拡大を牽引しています。

また、眼疾患の有病率の増加も黄斑浮腫と黄斑変性市場の成長に寄与すると期待されています。眼疾患には、視覚系に影響を与え、視力障害やその他の症状を引き起こすさまざまな疾患が含まれます。湿性加齢黄斑変性（AMD）などの疾患は、血管の異常な成長や漏れを引き起こし、黄斑部に液体を蓄積させる直接的な原因となります。例えば、2023年9月、英国政府のウェブサイトであるNational Eye Health Weekは、英国における失明の主な原因である後期加齢黄斑変性（AMD）は、2032年までに25％増加すると予測されると報告しています。さらに、早期AMD（ドルーゼン）は2032年までに16％、白内障は25％、緑内障は17％増加すると予測されています。このことは、黄斑浮腫と黄斑変性市場の成長を促進する上で、眼疾患の有病率の増加が重要であることを強調しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界黄斑浮腫と黄斑変性PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の黄斑浮腫と黄斑変性市場：成長率分析
• 世界の黄斑浮腫と黄斑変性市場の実績：規模と成長, 2019-2024
• 世界の黄斑浮腫と黄斑変性市場の予測：規模と成長, 2024-2029, 2034F
• 世界黄斑浮腫と黄斑変性総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の黄斑浮腫と黄斑変性市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬物療法
• レーザー治療
• 世界の黄斑浮腫と黄斑変性市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 黄斑浮腫
• 糖尿病黄斑浮腫（DME）
• 嚢胞様黄斑浮腫（CME）
• 黄斑変性症
• ドライ型加齢黄斑変性
• 滲出型加齢黄斑変性
• 世界の黄斑浮腫と黄斑変性市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• その他のエンドユーザー
• 世界の黄斑浮腫と黄斑変性市場、薬物療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗VEGF（血管内皮増殖因子）注射
• ステロイド注射
• 経口薬
• 併用療法（抗VEGF+ステロイド）
• 世界の黄斑浮腫と黄斑変性市場、レーザー治療のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 焦点レーザー光凝固術
• 汎網膜光凝固（PRP）
• 閾値下レーザー療法
• マイクロパルスレーザー療法

第7章 地域別・国別分析

• 世界の黄斑浮腫と黄斑変性市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の黄斑浮腫と黄斑変性市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 黄斑浮腫と黄斑変性市場：競合情勢
• 黄斑浮腫と黄斑変性市場：企業プロファイル
  • F. Hoffmann La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Amgen Inc.
• Regeneron Pharmaceuticals Inc.
• Biogen Inc.
• Bausch Health Companies Inc.
• Clover Therapeutics Inc.
• Santen Pharmaceutical Co. Ltd.
• Samsung Bioepis Inc.
• PanOptica Inc.
• Regen X Bio Inc.
• Aerie Pharmaceutical Inc.
• Apellis Pharmaceuticals Inc.
• Kubota Pharmaceutical Holdings Co. Ltd.
• Alimera Sciences Inc.
• Kodiak Sciences Inc.
• Acucela Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 黄斑浮腫と黄斑変性市場2029：新たな機会を提供する国
• 黄斑浮腫と黄斑変性市場2029：新たな機会を提供するセグメント
• 黄斑浮腫と黄斑変性市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Macular edema and macular degeneration are distinct eye conditions that can impact vision. Macular edema involves swelling in the retina's part at the back of the eye, leading to blurry vision. On the other hand, macular degeneration is a condition affecting the macula, which is responsible for central vision in the retina at the back of the eye. Both conditions can be triggered by various factors, including diabetic retinopathy, retinal vein occlusion, inflammation, as well as age, genetics, smoking, high blood pressure, and obesity.

The primary types of treatment for macular edema and macular degeneration include drug therapy and laser treatment. Drug therapy entails the use of pharmaceutical drugs or medications to address, manage, or alleviate medical conditions, diseases, or symptoms related to these eye conditions. It finds applications in treating macular edema, diabetic macular edema (DME), cystoid macular edema (CME), macular degeneration, dry age-related macular degeneration, and wet age-related macular degeneration. These treatments are administered by hospitals, clinics, and other end-users.

The macular edema and macular degeneration market research report is one of a series of new reports from The Business Research Company that provides macular edema and macular degeneration market statistics, including macular edema and macular degeneration industry global market size, regional shares, competitors with macular edema and macular degeneration market share, detailed macular edema and macular degeneration market segments, market trends and opportunities, and any further data you may need to thrive in the macular edema and macular degeneration industry. This macular edema and macular degeneration market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The macular edema and macular degeneration market size has grown strongly in recent years. It will grow from $9.65 billion in 2024 to $10.43 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to aging population, prevalence of diabetes, awareness and early diagnosis, global initiatives in eye health, pharmaceutical innovations, patient advocacy and support.

The macular edema and macular degeneration market size is expected to see strong growth in the next few years. It will grow to $13.71 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to personalized medicine approaches, rising awareness in emerging markets, focus on combination therapies, integration with teleophthalmology services, global aging demographics. Major trends in the forecast period include advancements in sustained-release drug delivery, integration of gene therapies, development of novel imaging technologies, personalized treatment approaches based on biomarkers, teleophthalmology for remote monitoring, advancements in artificial intelligence for diagnostics.

The increasing diabetes population is expected to drive the growth of the macular edema and macular degeneration market. Diabetes is a chronic condition characterized by elevated glucose (sugar) levels in the blood, which can damage the blood vessels in the eye, leading to macular edema and macular degeneration. For example, in June 2024, the National Health Service (NHS England), a UK-based publicly funded healthcare system, reported that in 2023, the number of individuals diagnosed with pre-diabetes in England rose to 3,615,330, an 18% increase from 3,065,825 in 2022. Additionally, cases among those under 40 saw a nearly 25% rise, growing from 173,166 in 2022 to 216,440 in 2023. Thus, the growing diabetes population is driving the expansion of the macular edema and macular degeneration market.

The increasing prevalence of eye disorders is also expected to contribute to the growth of the macular edema and macular degeneration market. Eye disorders encompass a diverse range of conditions affecting the visual system, leading to vision impairment or other symptoms. Conditions such as wet age-related macular degeneration (AMD) can result in abnormal blood vessel growth and leakage, directly contributing to fluid buildup in the macula. For instance, in September 2023, National Eye Health Week, a UK-based government website, reported that late-stage age-related macular degeneration (AMD), the primary cause of blindness in the UK, is projected to increase by 25% by 2032. Additionally, early-stage AMD (drusen) is expected to increase by 16%, cataracts by 25%, and glaucoma by 17% by 2032. This underscores the significance of the increasing prevalence of eye disorders in driving the growth of the macular edema and macular degeneration market.

Leading companies operating in the macular edema and macular degeneration market are directing their efforts towards developing innovative products, such as Vabysmo (faricimab-svoa), to enhance their market position. Vabysmo (faricimab-svoa) is a medication designed for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). For example, in January 2022, Genentech Inc., a US-based biotechnology corporation, received approval from the Food and Drug Administration for Vabysmo (faricimab-svoa). As a bispecific antibody targeting vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2), it represents the first bispecific monoclonal antibody for both disorders. The approval of Vabysmo marked a significant milestone for Genentech and Roche, positioning it as a potential blockbuster medication for the treatment of nAMD and DME.

In July 2024, Merck & Co. Inc., a US-based pharmaceutical and biotechnology company, acquired Eyebiotech Limited (Eyebio) for an undisclosed amount. This acquisition aims to strengthen and diversify Merck's late-stage pipeline by incorporating Restoret, an innovative late-phase candidate for treating diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD). The deal enhances Merck's portfolio with cutting-edge treatments rooted in novel biology and genetics, targeting unmet medical needs in retinal diseases. Eyebiotech Limited (Eyebio) is a US-based biotechnology company specializing in ophthalmology, developing therapies for sight-threatening eye diseases such as macular edema and macular degeneration.

Major companies operating in the macular edema and macular degeneration market report are F. Hoffmann La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, GlaxoSmithKline PLC, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Bausch Health Companies Inc., Clover Therapeutics Inc., Santen Pharmaceutical Co. Ltd., Samsung Bioepis Inc., PanOptica Inc., Regen X Bio Inc., Aerie Pharmaceutical Inc., Apellis Pharmaceuticals Inc., Kubota Pharmaceutical Holdings Co. Ltd., Alimera Sciences Inc., Kodiak Sciences Inc., Acucela Inc., Editas Medicine Inc., IVERIC bio Inc., Lineage Cell Therapeutics Inc., Allegro Ophthalmic Ltd., Ampio Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., Graybug Vision Inc., Clearside Biomedical Inc., Ocugen Inc., Opthea Limited

North America was the largest region in the macular edema and macular degeneration market in 2024. The regions covered in the macular edema and macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the macular edema and macular degeneration market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The macular edema and macular degeneration market consists of revenues earned by entities by providing services such as ophthalmic care, ophthalmologic evaluation, imaging and diagnostics, laser therapy, photodynamic therapy, and rehabilitation and low vision services. The market value includes the value of related goods sold by the service provider or included within the service offering. The macular edema and macular degeneration market also includes sales of surgical interventions, low vision aids, dietary supplements, retinal implants, and subretinal injections. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Macular Edema and Macular Degeneration Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on macular edema and macular degeneration market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for macular edema and macular degeneration ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The macular edema and macular degeneration market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Drug Therapy; Laser Treatment
• 2) By Application: Macular Edema; Diabetic Macular Edema (DME); Cystoid Macular Edema (CME); Macular Degeneration; Dry age-related macular degeneration; Wet age-related macular degeneration
• 3) By End User: Hospitals; Clinics; Other End Users
• Subsegments:
• 1) By Drug Therapy: Anti-VEGF (Vascular Endothelial Growth Factor) Injections; Steroid Injections; Oral Medications; Combination Therapy (Anti-VEGF + Steroids)
• 2) By Laser Treatment: Focal Laser Photocoagulation; Panretinal Photocoagulation (PRP); Subthreshold Laser Therapy; MicroPulse Laser Therapy
• Companies Mentioned: F. Hoffmann La Roche Ltd.; Abbvie Inc.; Bayer AG; Novartis AG; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Macular Edema and Macular Degeneration Market Characteristics

3. Macular Edema and Macular Degeneration Market Trends And Strategies

4. Macular Edema and Macular Degeneration Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Macular Edema and Macular Degeneration Growth Analysis And Strategic Analysis Framework

• 5.1. Global Macular Edema and Macular Degeneration PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Macular Edema and Macular Degeneration Market Growth Rate Analysis
• 5.4. Global Macular Edema and Macular Degeneration Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Macular Edema and Macular Degeneration Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Macular Edema and Macular Degeneration Total Addressable Market (TAM)

6. Macular Edema and Macular Degeneration Market Segmentation

• 6.1. Global Macular Edema and Macular Degeneration Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drug Therapy
• Laser Treatment
• 6.2. Global Macular Edema and Macular Degeneration Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Macular Edema
• Diabetic Macular Edema (DME)
• Cystoid Macular Edema (CME)
• Macular Degeneration
• Dry age-related macular degeneration
• Wet age-related macular degeneration
• 6.3. Global Macular Edema and Macular Degeneration Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Other End Users
• 6.4. Global Macular Edema and Macular Degeneration Market, Sub-Segmentation Of Drug Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-VEGF (Vascular Endothelial Growth Factor) Injections
• Steroid Injections
• Oral Medications
• Combination Therapy (Anti-VEGF + Steroids)
• 6.5. Global Macular Edema and Macular Degeneration Market, Sub-Segmentation Of Laser Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Focal Laser Photocoagulation
• Panretinal Photocoagulation (PRP)
• Subthreshold Laser Therapy
• MicroPulse Laser Therapy

7. Macular Edema and Macular Degeneration Market Regional And Country Analysis

• 7.1. Global Macular Edema and Macular Degeneration Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Macular Edema and Macular Degeneration Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Macular Edema and Macular Degeneration Market

• 8.1. Asia-Pacific Macular Edema and Macular Degeneration Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Macular Edema and Macular Degeneration Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Macular Edema and Macular Degeneration Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Macular Edema and Macular Degeneration Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Macular Edema and Macular Degeneration Market

• 9.1. China Macular Edema and Macular Degeneration Market Overview
• 9.2. China Macular Edema and Macular Degeneration Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Macular Edema and Macular Degeneration Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Macular Edema and Macular Degeneration Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Macular Edema and Macular Degeneration Market

• 10.1. India Macular Edema and Macular Degeneration Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Macular Edema and Macular Degeneration Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Macular Edema and Macular Degeneration Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Macular Edema and Macular Degeneration Market

• 11.1. Japan Macular Edema and Macular Degeneration Market Overview
• 11.2. Japan Macular Edema and Macular Degeneration Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Macular Edema and Macular Degeneration Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Macular Edema and Macular Degeneration Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Macular Edema and Macular Degeneration Market

• 12.1. Australia Macular Edema and Macular Degeneration Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Macular Edema and Macular Degeneration Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Macular Edema and Macular Degeneration Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Macular Edema and Macular Degeneration Market

• 13.1. Indonesia Macular Edema and Macular Degeneration Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Macular Edema and Macular Degeneration Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Macular Edema and Macular Degeneration Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Macular Edema and Macular Degeneration Market

• 14.1. South Korea Macular Edema and Macular Degeneration Market Overview
• 14.2. South Korea Macular Edema and Macular Degeneration Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Macular Edema and Macular Degeneration Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Macular Edema and Macular Degeneration Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Macular Edema and Macular Degeneration Market

• 15.1. Western Europe Macular Edema and Macular Degeneration Market Overview
• 15.2. Western Europe Macular Edema and Macular Degeneration Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Macular Edema and Macular Degeneration Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Macular Edema and Macular Degeneration Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Macular Edema and Macular Degeneration Market

• 16.1. UK Macular Edema and Macular Degeneration Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Macular Edema and Macular Degeneration Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Macular Edema and Macular Degeneration Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Macular Edema and Macular Degeneration Market

• 17.1. Germany Macular Edema and Macular Degeneration Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Macular Edema and Macular Degeneration Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Macular Edema and Macular Degeneration Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Macular Edema and Macular Degeneration Market

• 18.1. France Macular Edema and Macular Degeneration Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Macular Edema and Macular Degeneration Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Macular Edema and Macular Degeneration Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Macular Edema and Macular Degeneration Market

• 19.1. Italy Macular Edema and Macular Degeneration Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Macular Edema and Macular Degeneration Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Macular Edema and Macular Degeneration Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Macular Edema and Macular Degeneration Market

• 20.1. Spain Macular Edema and Macular Degeneration Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Macular Edema and Macular Degeneration Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Macular Edema and Macular Degeneration Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Macular Edema and Macular Degeneration Market

• 21.1. Eastern Europe Macular Edema and Macular Degeneration Market Overview
• 21.2. Eastern Europe Macular Edema and Macular Degeneration Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Macular Edema and Macular Degeneration Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Macular Edema and Macular Degeneration Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Macular Edema and Macular Degeneration Market

• 22.1. Russia Macular Edema and Macular Degeneration Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Macular Edema and Macular Degeneration Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Macular Edema and Macular Degeneration Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Macular Edema and Macular Degeneration Market

• 23.1. North America Macular Edema and Macular Degeneration Market Overview
• 23.2. North America Macular Edema and Macular Degeneration Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Macular Edema and Macular Degeneration Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Macular Edema and Macular Degeneration Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Macular Edema and Macular Degeneration Market

• 24.1. USA Macular Edema and Macular Degeneration Market Overview
• 24.2. USA Macular Edema and Macular Degeneration Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Macular Edema and Macular Degeneration Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Macular Edema and Macular Degeneration Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Macular Edema and Macular Degeneration Market

• 25.1. Canada Macular Edema and Macular Degeneration Market Overview
• 25.2. Canada Macular Edema and Macular Degeneration Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Macular Edema and Macular Degeneration Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Macular Edema and Macular Degeneration Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Macular Edema and Macular Degeneration Market

• 26.1. South America Macular Edema and Macular Degeneration Market Overview
• 26.2. South America Macular Edema and Macular Degeneration Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Macular Edema and Macular Degeneration Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Macular Edema and Macular Degeneration Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Macular Edema and Macular Degeneration Market

• 27.1. Brazil Macular Edema and Macular Degeneration Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Macular Edema and Macular Degeneration Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Macular Edema and Macular Degeneration Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Macular Edema and Macular Degeneration Market

• 28.1. Middle East Macular Edema and Macular Degeneration Market Overview
• 28.2. Middle East Macular Edema and Macular Degeneration Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Macular Edema and Macular Degeneration Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Macular Edema and Macular Degeneration Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Macular Edema and Macular Degeneration Market

• 29.1. Africa Macular Edema and Macular Degeneration Market Overview
• 29.2. Africa Macular Edema and Macular Degeneration Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Macular Edema and Macular Degeneration Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Macular Edema and Macular Degeneration Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Macular Edema and Macular Degeneration Market Competitive Landscape And Company Profiles

• 30.1. Macular Edema and Macular Degeneration Market Competitive Landscape
• 30.2. Macular Edema and Macular Degeneration Market Company Profiles
  • 30.2.1. F. Hoffmann La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Macular Edema and Macular Degeneration Market Other Major And Innovative Companies

• 31.1. Amgen Inc.
• 31.2. Regeneron Pharmaceuticals Inc.
• 31.3. Biogen Inc.
• 31.4. Bausch Health Companies Inc.
• 31.5. Clover Therapeutics Inc.
• 31.6. Santen Pharmaceutical Co. Ltd.
• 31.7. Samsung Bioepis Inc.
• 31.8. PanOptica Inc.
• 31.9. Regen X Bio Inc.
• 31.10. Aerie Pharmaceutical Inc.
• 31.11. Apellis Pharmaceuticals Inc.
• 31.12. Kubota Pharmaceutical Holdings Co. Ltd.
• 31.13. Alimera Sciences Inc.
• 31.14. Kodiak Sciences Inc.
• 31.15. Acucela Inc.

32. Global Macular Edema and Macular Degeneration Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Macular Edema and Macular Degeneration Market

34. Recent Developments In The Macular Edema and Macular Degeneration Market

35. Macular Edema and Macular Degeneration Market High Potential Countries, Segments and Strategies

• 35.1 Macular Edema and Macular Degeneration Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Macular Edema and Macular Degeneration Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Macular Edema and Macular Degeneration Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer